Perforation in colorectal stenting: a meta-analysis and a search for risk factors - 02/06/16
Abstract |
Background |
Recent studies suggest that there is a substantial risk of perforation after colorectal stent placement.
Objective |
To identify risk factors for perforation from colonic stenting.
Design |
A meta-analysis of 86 studies published between 2005 and 2011.
Setting |
Multicenter review.
Patients |
All patients who underwent colorectal stent placement.
Intervention |
Colorectal stent placement.
Main Outcome Measurements |
The occurrence of perforation with subgroup analyses for stent design, stricture etiology, stricture dilation, and concomitant chemotherapy, including the use of bevacizumab.
Results |
A total of 4086 patients underwent colorectal stent placement; perforation occurred in 207. Meta-analysis revealed an overall perforation rate of 7.4%. Of the 9 most frequently used stent types, the WallFlex, the Comvi, and the Niti-S D-type had a higher perforation rate (>10%). A lower perforation rate (<5%) was found for the Hanarostent and the Niti-S covered stent. Stenting benign strictures was associated with a significantly increased perforation rate of 18.4% compared with 7.5% for malignant strictures. Dilation did not increase the risk of perforation: 8.5% versus 8.5% without dilation. The subgroup of post-stent placement dilation had a significantly increased perforation risk of 20.4%. With a perforation rate of 12.5%, bevacizumab-based therapy was identified as a risk factor for perforation, whereas the risk for chemotherapy without bevacizumab was 7.0% and not increased compared with the group without concomitant therapies during stent therapy (9.0%).
Limitations |
Heterogeneity; a considerable proportion of data is unavailable for subgroup analysis.
Conclusions |
The perforation rate of colonic stenting is 7.4%. Stent design, benign etiology, and bevacizumab were identified as risk factors for perforation. Intraprocedural stricture dilation and concomitant chemotherapy were not associated with an increased risk of perforation.
Le texte complet de cet article est disponible en PDF.Abbreviations : CI, SEMS
Plan
| DISCLOSURE: The following authors disclosed financial relationships relevant to this publication: Dr van Hooft is a consultant for Boston Scientific and Cook Endoscopy. Dr Repici is a speaker and consultant for Boston Scientific and has received a research grant from Cook Medical. Dr Fockens is a consultant for Cook Endoscopy, Boston Scientific, and Olympus. All other authors disclosed no financial relationships relevant to this publication. |
|
| If you would like to chat with an author of this article, you may contact Dr van Hooft at j.e.vanhooft@amc.uva.nl. |
|
| See CME section; p. 983. |
Vol 79 - N° 6
P. 970 - juin 2014 Retour au numéro
Article précédent
- Metabolic syndrome and smoking may justify earlier colorectal cancer screening in men
- Li-Chun Chang, Ming-Shiang Wu, Chia-Hung Tu, Yi-Chia Lee, Chia-Tung Shun, Han-Mo Chiu
- Continuing Medical Education Exam: June 2014
- James Buxbaum, William Ross, Shou-Jiang Tang, Brian Weston, G.S. Raju, Glenn M. Eisen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?